Literature DB >> 7698009

Chromosomal mapping of the genes for the human cell cycle proteins cyclin C (CCNC), cyclin E (CCNE), p21 (CDKN1) and KAP (CDKN3).

D J Demetrick1, S Matsumoto, G J Hannon, K Okamoto, Y Xiong, H Zhang, D H Beach.   

Abstract

Many gene products associated with the cdk cell cycle kinases are thought to regulate the active kinase complex and thus regulate the transition points of the cell cycle. Genes encoding these proteins may potentially function as oncogenes or tumor suppressor genes. We describe the chromosomal mapping by FISH of the genes for several cdk-associated proteins including human CCNC (cyclin C) to 6q21, CCNE (cyclin E) to 19q12-->q13, CDKN1 (p21) to 6p21.2 and CDKN3 (KAP to 14q22). Some of these sites are near chromosomal translocations or LOH sites common to a variety of human tumors. The potential role for each of these genes in neoplasia is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7698009     DOI: 10.1159/000133960

Source DB:  PubMed          Journal:  Cytogenet Cell Genet        ISSN: 0301-0171


  15 in total

1.  PP2A:B56{epsilon}, a substrate of caspase-3, regulates p53-dependent and p53-independent apoptosis during development.

Authors:  Zhigang Jin; Lindsay Wallace; Scott Q Harper; Jing Yang
Journal:  J Biol Chem       Date:  2010-08-31       Impact factor: 5.157

2.  miR-132 targeting cyclin E1 suppresses cell proliferation in osteosarcoma cells.

Authors:  Jin Wang; Guoxing Xu; Feng Shen; Yifan Kang
Journal:  Tumour Biol       Date:  2014-01-22

3.  Synergistic repression of thyroid hyperplasia by cyclin C and Pten.

Authors:  Jan Jezek; Kun Wang; Ruilan Yan; Antonio Di Cristofano; Katrina F Cooper; Randy Strich
Journal:  J Cell Sci       Date:  2019-08-15       Impact factor: 5.285

4.  CDKN3 knockdown reduces cell proliferation, invasion and promotes apoptosis in human ovarian cancer.

Authors:  Li-Ping Zhang; Wen-Juan Li; Yuan-Fang Zhu; Shu-Ying Huang; Shan-Yu Fang; Li Shen; Yan-Ling Gao
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  Circadian variation in expression of G1 phase cyclins D1 and E and cyclin-dependent kinase inhibitors p16 and p21 in human bowel mucosa.

Authors:  John Griniatsos; Othon P Michail; Stamatios Theocharis; Antonios Arvelakis; Ioannis Papaconstantinou; Evangelos Felekouras; Emmanouel Pikoulis; Ioannis Karavokyros; Chris Bakoyiannis; George Marinos; John Bramis; Panayiotis O Michail
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

6.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

7.  Choline availability modulates human neuroblastoma cell proliferation and alters the methylation of the promoter region of the cyclin-dependent kinase inhibitor 3 gene.

Authors:  Mihai D Niculescu; Yutaka Yamamuro; Steven H Zeisel
Journal:  J Neurochem       Date:  2004-06       Impact factor: 5.372

8.  Overexpression of kinase-associated phosphatase (KAP) in breast and prostate cancer and inhibition of the transformed phenotype by antisense KAP expression.

Authors:  S W Lee; C L Reimer; L Fang; M L Iruela-Arispe; S A Aaronson
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 5.069

9.  Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray.

Authors:  Y Hedberg; B Ljungberg; G Roos; G Landberg
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

10.  Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer.

Authors:  Ana María Espinosa; Ana Alfaro; Edgar Roman-Basaure; Mariano Guardado-Estrada; Ícela Palma; Cyntia Serralde; Ingrid Medina; Eligia Juárez; Miriam Bermúdez; Edna Márquez; Manuel Borges-Ibáñez; Sergio Muñoz-Cortez; Avissai Alcántara-Vázquez; Patricia Alonso; José Curiel-Valdez; Susana Kofman; Nicolas Villegas; Jaime Berumen
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.